Canakinumab - CISMeF

Preferred Label : Canakinumab;

NCIt definition : A recombinant monoclonal antibody targeting human interleukin-1 beta (IL-1b), with anti-inflammatory and immunomodulating activities. Canakinumab binds IL-1b and prevents the binding of IL-1b to the IL-1 receptor and inhibits IL-1b-mediated signaling. This may suppress inflammatory responses mediated by IL-1b. IL-1b, a proinflammatory cytokine, plays a key role in inflammation.;

UNII : 37CQ2C7X93;

CAS number : 914613-48-2;

Drug name : Ilaris;

Molecule name : ACZ885;

Détails

Origin ID

C80971;

UMLS CUI

C2718773;

CISMeF manual mappings
- Canakinumab (substance) [SNOMED CT concept]
See also inter- (CISMeF)
- Product containing canakinumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Canakinumab (substance) [SNOMED CT concept]
- Product containing canakinumab (medicinal product) [SNOMED CT concept]
- canakinumab [ATC Code]
- canakinumab [MeSH concept]
- canakinumab [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- canakinumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]
has_target
- Interleukin-1 Beta [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients